4D Lifetec

Executive Summary

4D Lifetec AG is a Swiss diagnostics startup founded in 2017, headquartered in Zurich, developing the 4D Lifetest™, a non-invasive blood test for early cancer detection. The test leverages an immuno-oncological approach to detect multiple cancer types at early stages, aiming to improve patient outcomes through timely intervention. The company positions its technology as a standardized, cost-effective, and ultra-precise tool for critical care phases, addressing a significant unmet need in oncology diagnostics. As a private company with no disclosed funding or valuation, 4D Lifetec is in early development stages, but its focus on liquid biopsy and early detection aligns with a rapidly growing market. The company's success depends on clinical validation and regulatory clearance, which would differentiate it from existing liquid biopsy competitors. With a strong value proposition in non-invasive, multi-cancer screening, 4D Lifetec has potential to become a key player if it achieves robust clinical data and secures partnerships or funding for commercialization.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase I Clinical Trial60% success
• Q1 2027Publication of Proof-of-Concept Data70% success
• TBDStrategic Partnership or Licensing Deal50% success